MDMA-Assisted Therapy for Pathological Narcissism

This open-label, proof-of-concept pilot study (n=12) will assess the efficacy and safety of midomafetamine (MDMA)-assisted therapy (MDMA-AT) (80 mg for the first session, 120 mg for the second and third, with an optional supplemental dose of 50% of the initial dose) for participants diagnosed with pathological narcissism.

Conducted by the University of Washington and led by Dr Anthony Back, the study will involve a screening period, three preparation sessions, three monthly experimental therapy sessions with MDMA, and nine integration sessions. Follow-ups will be conducted at one week, one month, three months, and six months post-treatment.

Participants will be required to have an identified family member and psychotherapist as informants. The trial aims to evaluate the impact of MDMA-AT on pathological narcissism symptoms, with study completion expected by early 2027.

Topic Personality

Compound MDMA

Country United States of America

Visit trial

Trial Details

Trial Number

Sponsors & Collaborators

University of Washington in Seattle
Research into the therapeutic potential of psychedelics is underway at Washington State University.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.